Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9247 |
High Similarity |
NPD1653 |
Approved |
0.8562 |
High Similarity |
NPD7266 |
Discontinued |
0.8403 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8403 |
Intermediate Similarity |
NPD1613 |
Approved |
0.8395 |
Intermediate Similarity |
NPD7054 |
Approved |
0.8344 |
Intermediate Similarity |
NPD7472 |
Approved |
0.8344 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.8333 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.8303 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.825 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.8228 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.82 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.8194 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.8193 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.8182 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.8176 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.8165 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.8153 |
Intermediate Similarity |
NPD37 |
Approved |
0.8133 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.8125 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8113 |
Intermediate Similarity |
NPD4965 |
Approved |
0.8113 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.8113 |
Intermediate Similarity |
NPD4966 |
Approved |
0.8061 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.8056 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8038 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8037 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.8024 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.8014 |
Intermediate Similarity |
NPD1091 |
Approved |
0.8012 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.8 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7961 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7949 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7879 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7879 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7879 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7875 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7852 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7852 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7811 |
Intermediate Similarity |
NPD7240 |
Approved |
0.777 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7764 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7764 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7764 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7764 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7762 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7756 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7751 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7738 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.773 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7716 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7687 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7669 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7661 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.7654 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7644 |
Intermediate Similarity |
NPD6842 |
Approved |
0.7644 |
Intermediate Similarity |
NPD6841 |
Approved |
0.7644 |
Intermediate Similarity |
NPD6843 |
Phase 3 |
0.7643 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7635 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7616 |
Intermediate Similarity |
NPD1933 |
Approved |
0.761 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7602 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7595 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7593 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7578 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7547 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7534 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7534 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7533 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7532 |
Intermediate Similarity |
NPD1511 |
Approved |
0.753 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7517 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7517 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7516 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7485 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7483 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7471 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7466 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7452 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.744 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.744 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7438 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7434 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7429 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7423 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7417 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7415 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.741 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7403 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7389 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7386 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7368 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7362 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7358 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7342 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7342 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7333 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7329 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7325 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7314 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7314 |
Intermediate Similarity |
NPD8313 |
Approved |
0.731 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.731 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7308 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7292 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7273 |
Intermediate Similarity |
NPD4340 |
Discontinued |
0.7273 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7273 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7262 |
Intermediate Similarity |
NPD919 |
Approved |
0.7261 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7261 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7261 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7261 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7248 |
Intermediate Similarity |
NPD3225 |
Approved |
0.7244 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7239 |
Intermediate Similarity |
NPD3686 |
Approved |
0.7239 |
Intermediate Similarity |
NPD3687 |
Approved |
0.7237 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7237 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7233 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7222 |
Intermediate Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.7222 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7215 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.7212 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7207 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7205 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.72 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7197 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.719 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7183 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7181 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7179 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7179 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7179 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7174 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7171 |
Intermediate Similarity |
NPD1008 |
Clinical (unspecified phase) |
0.7171 |
Intermediate Similarity |
NPD6832 |
Phase 2 |
0.717 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.716 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.716 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7152 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7143 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7134 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7133 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7125 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7125 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7112 |
Intermediate Similarity |
NPD7680 |
Approved |
0.7102 |
Intermediate Similarity |
NPD7039 |
Approved |
0.7102 |
Intermediate Similarity |
NPD7038 |
Approved |
0.7097 |
Intermediate Similarity |
NPD4140 |
Approved |
0.709 |
Intermediate Similarity |
NPD7583 |
Approved |
0.7089 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7089 |
Intermediate Similarity |
NPD6032 |
Approved |
0.7089 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7083 |
Intermediate Similarity |
NPD5353 |
Approved |
0.7083 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.7083 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7078 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7071 |
Intermediate Similarity |
NPD1358 |
Approved |
0.7071 |
Intermediate Similarity |
NPD290 |
Approved |
0.707 |
Intermediate Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.7063 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7053 |
Intermediate Similarity |
NPD7585 |
Approved |
0.7052 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7051 |
Intermediate Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.7048 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7048 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7034 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7032 |
Intermediate Similarity |
NPD4062 |
Phase 3 |
0.7027 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7025 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7025 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7025 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7021 |
Intermediate Similarity |
NPD2684 |
Approved |
0.702 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7018 |
Intermediate Similarity |
NPD5677 |
Discontinued |
0.7006 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD6971 |
Discontinued |
0.6994 |
Remote Similarity |
NPD3926 |
Phase 2 |
0.6994 |
Remote Similarity |
NPD5242 |
Approved |
0.6993 |
Remote Similarity |
NPD228 |
Approved |
0.6988 |
Remote Similarity |
NPD8158 |
Clinical (unspecified phase) |
0.6988 |
Remote Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.6988 |
Remote Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.6983 |
Remote Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.6977 |
Remote Similarity |
NPD6959 |
Discontinued |
0.6975 |
Remote Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.6975 |
Remote Similarity |
NPD2677 |
Approved |
0.6968 |
Remote Similarity |
NPD1296 |
Phase 2 |
0.6959 |
Remote Similarity |
NPD5691 |
Approved |
0.6957 |
Remote Similarity |
NPD5177 |
Phase 3 |
0.6951 |
Remote Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.6937 |
Remote Similarity |
NPD1375 |
Discontinued |
0.6936 |
Remote Similarity |
NPD7229 |
Phase 3 |
0.6927 |
Remote Similarity |
NPD8151 |
Discontinued |
0.6923 |
Remote Similarity |
NPD2978 |
Approved |
0.6923 |
Remote Similarity |
NPD2977 |
Approved |
0.6918
|
Remote Similarity |
NPD4308 |
Phase 3 |